Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05224154 · ClinicalTrials.gov registry record · NA

Re-Connect Application for Smoking Cessation

A NA study of Smoking Cessation and Acceptability of Health Care, sponsored by Rowan University.

Recruiting
Registry status
NA
Development phase
82
Enrollment target
1
Study location

NCT05224154 is a NA study of Smoking Cessation and Acceptability of Health Care that is actively recruiting participants, run by Rowan University. The registered enrollment target is 82 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05224154, a NA study of Smoking Cessation and Acceptability of Health Care, is actively recruiting participants, sponsored by Rowan University.

RECRUITING
Registry status
NA
Development phase
82 participants
Enrollment target
1
Study location

Study Summary

This series of studies will explore the acceptability, feasibility, and preliminary efficacy of making access to smartphone applications contingent on objective evidence of smoking abstinence.

Interventions

  • BEHAVIORAL Abstinent Contingent (AC) Re-Connect
  • BEHAVIORAL Submission Contingent (SC) Re-Connect

Study Locations (1)

New Jersey

  • Rowan University - Glassboro

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2021-12-14
Est. Completion 2026-03-31
Phase NA

Sponsor

Rowan University

19 total trials

What the Registry Record Tells You About NCT05224154

The ClinicalTrials.gov registry entry for NCT05224154 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (83% lower). The listed sponsor is Rowan University, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Abstinent Contingent (AC) Re-Connect is the first listed.

NCT05224154 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT05224154 about?

NCT05224154 is a clinical study titled "Re-Connect Application for Smoking Cessation". This series of studies will explore the acceptability, feasibility, and preliminary efficacy of making access to smartphone applications contingent on objective evidence of smoking abstinence.

What is the current status of trial NCT05224154?

This trial is currently recruiting. It is a NA study. The enrollment target is 82 participants. The study started on 2021-12-14. Estimated completion is 2026-03-31.

What conditions does trial NCT05224154 study?

This clinical trial studies the following conditions: Smoking Cessation, Acceptability of Health Care, Nicotine Dependence, Cigarettes.

What interventions are being tested in trial NCT05224154?

The interventions under investigation include: Abstinent Contingent (AC) Re-Connect (BEHAVIORAL), Submission Contingent (SC) Re-Connect (BEHAVIORAL).

Who is sponsoring clinical trial NCT05224154?

This trial is sponsored by Rowan University, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05224154 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.